Multi-chemokine receptor antagonist RAP-103 inhibits opioid-derived respiratory depression, reduces opioid reinforcement and physical dependence, and normalizes opioid-induced dysregulation of mesolimbic chemokine receptors in rats
Year: 2022
Type: article
Source: Drug and Alcohol Dependence
Authors: Angela R. Bongiovanni, Pingwei Zhao, Saadet Inan, Sonita Wiah, Aryan Shekarabi, Daniel J. Farkas, Mia N. Watson, Mathieu E. Wimmer, Michael R. Ruff, Scott M. Rawls
Institution: Temple University
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: bronze
Funder: National Institute on Drug Abuse
Awards: Development of a Novel Chemokine Receptor Antagonist as a Treatment for Opioid Use Disorder, Chemokine CXCL12/CXCR4 system and synthetic cathinones, Center on Intersystem Regulation by Drugs of Abuse, G3620553847, Unraveling epigenetic mechanisms of opioid addiction susceptibility using multigenerational animal models, A Novel Chemokine Receptor Antagonist to Block Opioid Reinforcement, Relapse and Physical Dependence, Neurobiology of Addiction Training Program
OpenAlex ID: W4285011836